STIM
Neuronetics, Inc.
STIM lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
STIM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
STIM's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
STIM PE Valuation
STIM has no meaningful PE right now: it lost money over the past year.
STIM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect STIM's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
STIM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.33 | +$0.50 |
| Q2 2026 | -$0.44 | +$0.70 |
| Q1 2026 | -$0.54 | +$0.78 |
| Q4 2025 | -$0.59 | +$0.79 |
| Q3 2025 | -$0.83 | +$0.38 |
| Q2 2025 | -$1.14 | -$0.04 |
| Q1 2025 | -$1.32 | -$0.38 |
| Q4 2024 | -$1.38 | -$0.33 |
STIM is still losing money, but far less than before: $0.33 per share over the past year, against $1.87 at its worst in mid-2020.
STIM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42M | +13% |
| Q2 2026 | $41.6M | +9.1% |
| Q1 2026 | $34.5M | +7.8% |
| Q4 2025 | $41.8M | +86% |
| Q3 2025 | $37.3M | +101% |
| Q2 2025 | $38.1M | +132% |
| Q1 2025 | $32M | +84% |
| Q4 2024 | $22.5M | +11% |
STIM's revenue has grown year over year for nine quarters in a row: $42M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.3% | +21 points |
| Q2 2026 | -3.6% | +18 points |
| Q1 2026 | -26% | +8.3 points |
| Q4 2025 | -12% | +39 points |
| Q3 2025 | -20% | +22 points |
| Q2 2025 | -21% | +31 points |
| Q1 2025 | -34% | +4.9 points |
| Q4 2024 | -51% | -29 points |
STIM's operating margin was 1.3% last quarter, up 21 points from the same quarter a year ago, near the top of its range since 2019.
STIM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $768K | +$1.7M |
| Q2 2026 | -$1.4M | +$2.3M |
| Q1 2026 | -$9.6M | +$7.6M |
| Q4 2025 | $692K | +$9.4M |
| Q3 2025 | -$899K | +$4.9M |
| Q2 2025 | -$3.8M | +$1.8M |
| Q1 2025 | -$17.2M | -$4.8M |
| Q4 2024 | -$8.7M | -793% |
STIM has burned cash in almost every quarter: −$10M over the past year, against −$31M the year before.
STIM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.3% | +3.9M shares |
| 1 year | +14% | +9.7M shares |
| 3 years | +169% | +48.4M shares |
| 5 years | +197% | +51.1M shares |
| Available history | +313% | +58.4M shares |
STIM has 77M diluted shares, up 14% from a year ago.
STIM Net Leverage
STIM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
STIM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.4 | Neutral |
| Stochastic | 17.8 | Oversold |
STIM's weekly RSI is 39 (neutral) and its Stochastic is 18 (oversold).
STIM PE vs Healthcare Sector
STIM has no meaningful PE right now: it lost money over the past year.
STIM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.11 | 32% below |
| 20 week MA | $2.29 | 38% below |
| 50 week MA | $1.82 | 21% below |
| 100 week MA | $2.57 | 44% below |
| 200 week MA | $2.47 | 42% below |
STIM is in a downtrend: it's below all five of its weekly moving averages, and 42% below its 200-week average.
STIM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.50 | $10.7 | +137% |
| 2021 | $10.7 | $4.60 | -57% |
| 2022 | $4.60 | $5.97 | +30% |
| 2023 | $5.97 | $2.90 | -51% |
| 2024 | $2.90 | $1.48 | -49% |
| 2025 | $1.48 | $1.42 | -4.1% |
| 2026 YTD | $1.42 | $1.43 | +0.7% |
STIM has finished three years in a row lower, and it's up 0.7% so far in 2026.